SYSTEMIC AND MUCOSAL IMMUNE RESPONSES IN MICE AFTER INTRANASAL IMMUNIZATION WITH PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINES WITH RECOMBINANT CHOLERA TOXIN B SUBUNIT AS AN ADJUVANT

概要

論文の詳細を見る
Host defense mechanisms against Streptococcus pneumoniae largely depend on phagocytosis following opsonization by polysaccharide-specific immunoglobulin G (IgG) antibodies and complement. Since colonization in the respiratory mucosa is the first step in pneumococcal pathogenesis, mucosal immune responses may play a significant role. In addition to indueing systemic immune responses, mucosal vaccination with an effective adjuvant has the advantage of inducing mucosal IgA antibodies. The recombinant cholera toxin B subunit (rCTB) is a well-studied mucosal adjuvant, and adjuvant activity of rCTB has been demonstrated for several protein antigens. We investigated the immunogenicity of pneumococcal polysaccharide (PPS) conjugate vaccines of serotypes 3 and 14 in mice after intranasal (i. n.) immunization by using as an adjuvant rCTB, which has no toxicity. Pneumococcal serotype-specific antibodies were measured in serum (IgG, IgG 1 and IgA) and lung lavage fluid (IgA). When coadministered with rCTB, i. n. immunization with PPS-diphtheria toxoid (DT) conjugate induced systemic and mucosal immune responses, and serum IgG 1 antibody levels were significantly higher than PPS-rCTB conjugate mixed with rCTB. These results demonstrate that i. n. vaccination with PPS-DT conjugate with rCTB as an adjuvant can elicit systemic and mucosal immune responses in mice, indicating that the mucosal vaccination may be an alternative vaccination strategy for humans.
名古屋市立大学の論文

SYSTEMIC AND MUCOSAL IMMUNE RESPONSES IN MICE AFTER INTRANASAL IMMUNIZATION WITH PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINES WITH RECOMBINANT CHOLERA TOXIN B SUBUNIT AS AN ADJUVANT

スポンサーリンク

概要

著者

関連論文

スポンサーリンク